CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 2017—Cofactor Genomics launched its Pinnacle assay, which looks at gene fusions and gene expression in patient tumor samples to provide physicians with potential treatment targets for cancer patients. Pinnacle measures the RNA expression of nearly 400 prominent cancer genes, identifies those with oncogenic expression, and enables identification of more than 180 critical cancer-associated gene fusions from any type of formalin-fixed solid tumor. The assay is approved for use with more than 25 cancer types, with clinical validation.
The test is available through the company’s laboratory in St. Louis, which holds a CLIA certificate of accreditation from the CAP.
Cofactor Genomics
, 314-531-4647